Physician profile
Adel Dimassi
NPI 1538781935
$1,513.42
in general payments reported to CMS, 2019-2025
19 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.20 · 2023: $440 · 2024: $753 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $291.93 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals Lp | $250.97 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $243.63 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $121.71 | 2023-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $77.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.65 | 2023-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $68.24 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $52.18 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $47.12 | 2023-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.44 | 2023-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $38.79 | 2023 | Austedo Xr |
| Lundbeck LLC | $37.03 | 2023-2024 | Vyepti |
| Xeris Pharmaceuticals, INC. | $34.38 | 2023-2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $29.26 | 2024 | |
| Exact Sciences Corporation | $26.75 | 2023-2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.17 | 2025 | |
| Hologic Sales and Service, LLC | $18.89 | 2024 | Aptima |
| Amgen INC. | $16.74 | 2024 | Otezla, Repatha |
| Alkermes, INC. | $14.34 | 2025 | Aristada, Aristada Initio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Dimassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.